Recently, the National Center for Clinical Laboratories (NCCL) of the National Health Commission announced the 2023 external quality assessment results for the national clinical laboratory "High-Throughput Sequencing Detection of Somatic Mutations in Solid Tumors." ProteinT Medical Laboratory (Tianjin Baikang Hexin Medical Laboratory), the independent clinical trial execution window under ProteinT, again passed this external quality assessment with a perfect score.

External Quality Assessment Results

The National External Quality Assessment Program for High-Throughput Sequencing Detection of Somatic Mutations in Solid Tumors is an important means of ensuring the testing quality of clinical laboratories. This external quality assessment program can determine the capability of participating laboratories in high-throughput sequencing detection of somatic mutations in solid tumors; and identify common problems existing in the detection process as well as specific problems in certain laboratories, so as to promote laboratories to improve their detection standards.

ProteinT has always adhered to high standards and strict requirements, providing high-quality clinical testing services. In this external quality assessment, the analysis results for mutation types including SNV, InDel, CNV, and SV submitted were fully consistent with expectations, all passing with perfect scores. This fully reflects our company's professional testing and analytical capabilities and powerfully demonstrates the team's solid technical strength. In the future, ProteinT will, as always, meticulously build a standardized and normalized quality control system, continuously improve the laboratory's technical service level, and continue to provide high-quality products and professional services to doctors and patients!

About Tianjin Baikang Hexin Medical Laboratory

Tianjin Baikang Hexin Medical Laboratory is the independent clinical trial execution window under ProteinT. It is a national high-tech enterprise and a for-profit medical institution approved by the Health Commission, equipped with an Illumina NextSeq 500 sequencing system, Thermo Fisher Q-Exactive+/HF, AB SCIEX 4500 mass spectrometry system, and Bruker Avance III IVDr nuclear magnetic resonance spectrometer detection platform, with a total value of over 90 million yuan. It has cumulatively served over a hundred tertiary hospitals and research institutes, with a sample volume of over 100,000 cases.

About External Quality Assessment

External Quality Assessment (EQA), also known as proficiency testing, is an internationally recognized important component of comprehensive quality management in clinical laboratories, and an important tool for health administrative departments and hospital administrators to supervise laboratory quality. It plays a very important and positive role in ensuring and improving clinical testing quality and advancing the standardization of clinical testing.

Since 2023, ProteinT has successively passed the external quality assessment for Septin9 gene methylation and the external quality assessment for bioinformatics analysis of high-throughput sequencing detection of somatic mutations in solid tumors nationwide.